These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 29753194)

  • 1. Targeting WNT signaling in the treatment of osteoporosis.
    Baron R; Gori F
    Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One year in review 2018: progress in osteoporosis treatment.
    Figliomeni A; Signorini V; Mazzantini M
    Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
    Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
    J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism.
    Hasan WNW; Chin KY; Jolly JJ; Ghafar NA; Soelaiman IN
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):450-457. PubMed ID: 29683099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway.
    Appelman-Dijkstra NM; Papapoulos SE
    Nat Rev Endocrinol; 2018 Oct; 14(10):605-623. PubMed ID: 30181608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
    Quemerais-Durieu MA; Kerlan V; Chabre O
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological agents and natural compounds: available treatments for osteoporosis.
    Martiniakova M; Babikova M; Omelka R
    J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
    Marini F; Giusti F; Palmini G; Brandi ML
    Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
    Canalis E
    Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches.
    Canalis E
    Nat Rev Endocrinol; 2013 Oct; 9(10):575-83. PubMed ID: 23938284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab in the treatment of glucocorticoid-induced osteoporosis.
    Coskun Benlidayi I
    Rheumatol Int; 2018 Nov; 38(11):1975-1984. PubMed ID: 30019224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on osteoporosis therapies.
    Cairoli E; Zhukouskaya VV; Eller-Vainicher C; Chiodini I
    J Endocrinol Invest; 2015 Mar; 38(3):303-11. PubMed ID: 25577263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin and Bone Aging: A Mini-Review.
    Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
    Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.